The online version of this article (doi:10.1186/1475-2840-11-153) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests
FM, AMM and LG: design, data collection, drawing the manuscript, data analysis and statistics. All authors: design, critical revision of article and approval of article.
In diabetes, a variety of pro-inflammatory cellular changes has been found in various cell types, including monocytes which are known to be involved in all the phases of atherogenesis. Angiotensin II (Ang II) type 1 receptor (AT1R) mediates the pro-atherogenic effects of Ang II whereas the type 2 receptor (AT2R) seems associated with atheroprotection. We sought to investigate the potential changes of AT1R-AT2R expression in human monocytes of type 2 diabetic- hypercholesterolemic patients and in hypercholesterolemic subjects, upon clinical treatment with rosuvastatin.
The AT1R membrane protein and mRNA AT1R and AT2R expression in monocytes were investigated in 10 type 2 diabetic-hypercholesterolemic patients and in 10 hypercholesterolemic subjects, before and after 3-month rosuvastatin treatment. Moreover, the serum cytokine levels of interferon-γ (IFN-γ) and interleukin-4 (IL-4) were detected.
As expected, rosuvastatin was associated with a change in the lipid profile in the two groups. Both the membrane protein (P = 0.008) and the AT1R mRNA expression (P = 0.038) were significantly reduced during treatment in the absence of AT2R expression change in diabetic-hypercholesterolemic patients whereas no significant difference was observed in hypercholesterolemic subjects. The serum IL-4 levels were increased during treatment whereas no change was observed in IFN-γ in diabetic-hypercholesterolemic patients. No cytokine change was observed in hypercholesterolemic subjects.
Our study on monocytes of diabetic-hypercholesterolemic patients, showing a reduced AT1R but not AT2R expression during rosuvastatin treatment, suggests that statin therapy may modulate favorably the AT1-AT2 receptor balance in subjects with coexistent type 2 diabetes.
Additional file 1: Laboratory characteristics of patients at baseline. (DOC 38 KB)12933_2012_583_MOESM1_ESM.doc
Authors’ original file for figure 112933_2012_583_MOESM2_ESM.pdf
Authors’ original file for figure 212933_2012_583_MOESM3_ESM.pdf
Authors’ original file for figure 312933_2012_583_MOESM4_ESM.pdf
Tone A, Shikata K, Ogawa D, Sasaki S, Nagase R, Sasaki M, Yozai K, Usui HK, Okada S, Wada J, Shikata Y, Makino H: hanges of gene expression profiles in macrophages stimulated by angiotensin II-angiotensin II induces MCP-2 through AT1-receptor. J Renin Angiotensin Aldosterone Syst. 2007, 8: 45-50. 10.3317/jraas.2007.007. CrossRefPubMed
Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008, 371: 117-125. 10.1016/S0140-6736(08)60104-X. CrossRef
Marino F, Guasti L, Cosentino M, Ferrari M, Rasini E, Maio RC, Cimpanelli MG, Cereda E, Crespi C, Simoni C, Restelli D, Venco A, Lecchini S: Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. J Cardiovasc Pharmacol. 2007, 49: 299-305. 10.1097/FJC.0b013e31803d35ce. CrossRefPubMed
Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G: Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol. 2010, 299: F1203-F1211. 10.1152/ajprenal.00045.2010. CrossRefPubMed
Marino F, Guasti L, Cosentino M, Rasini E, Ferrari M, Maio RC, Loraschi A, Cimpanelli MG, Schembri L, Legnaro M, Molteni E, Crespi C, Crema F, Venco A, Lecchini S: Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008, 26: 1147-1155. 10.1097/HJH.0b013e3282f97dde. CrossRefPubMed
Guasti L, Marino F, Cosentino M, Cimpanelli M, Maio RC, Klersy C, Crespi C, Restelli D, Simoni C, Franzetti I, Gaudio G, Marnini P, Grandi AM, Lecchini S, Venco A: Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. J Hypertens. 2006, 24: 2423-2430. 10.1097/01.hjh.0000251903.62804.77. CrossRefPubMed
Guasti L, Marino F, Cosentino M, Maio RC, Rasini E, Ferrari M, Castiglioni L, Klersy C, Gaudio G, Grandi AM, Lecchini S, Venco A: Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur Heart J. 2008, 29 (9): 1118-1126. 10.1093/eurheartj/ehn138. CrossRefPubMed
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: For the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. N Engl J Med. 1994, 330: 877-884. 10.1056/NEJM199403313301301. CrossRefPubMed
Ihara Y, Egashira K, Nakano K, Ohtani K, Kubo M, Koga J, Iwai M, Horiuchi M, Gang Z, Yamagishi S, Sunagawa K: Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J Mol Cell Cardiol. 2007, 43: 455-464. 10.1016/j.yjmcc.2007.07.044. CrossRefPubMed
Reuter H, Adam C, Grönke S, Zobel C, Frank KF, Müller-Ehmsen J, Brabender J, Schwinger RH: The increased angiotensin II (type 1) receptor density in myocardium of type 2 diabetic patients is prevented by blockade of the renin-angiotensin system. Diabetologia. 2006, 49: 3067-3074. 10.1007/s00125-006-0444-8. CrossRefPubMed
Hodroj W, Legedz L, Foudi N, Cerutti C, Bourdillon MC, Feugier P, Beylot M, Randon J, Bricca G: Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol. 2007, 27: 525-531. 10.1161/01.ATV.0000254814.63768.3b. CrossRefPubMed
Van de Wal RM, van der Harst P, Wagenaar LJ, Wassmann S, Morshuis WJ, Nickenig G, Buikema H, Plokker HW, van Veldhuisen DJ, van Gilst WH, Voors AA: Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease. J Cardiovasc Pharmacol. 2007, 50: 372-379. 10.1097/FJC.0b013e31811ea222. CrossRefPubMed
Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic. Arterioscler Thromb Vasc Biol. 2002, 22: 1194-1199. 10.1161/01.ATV.0000022694.16328.CC. CrossRefPubMed
- Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment
Andrea Maria Maresca
Ramona C Maio
Anna Maria Grandi
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II